FDA updates guidance for adaptive clinical trial reporting
The US Food and Drug Administration has announced new guidance for drug applications that include results from adaptive clinical trials.
List view / Grid view
News
Dr Richard Torbett named as new ABPI Chief Executive
The ABPI’s board has unanimously appointed Dr Richard Torbett as Chief Executive, commencing 1 January 2020.
Priority Review granted to pemigatinib for treatment of cholangiocarcinoma
The US FDA has awarded pemigatinib Priority Review, after the drug met its primary and secondary endpoints in a Phase II trial.
Campaign calls for more effort to combat counterfeit medicines
A week-long awareness-raising campaign has been launched to combat the spread of substandard and falsified medicines.
NICE approves breast cancer treatment through Cancer Drugs Fund
NICE has approved palbociclib through the Cancer Drugs Fund, meaning that women with advanced breast cancer who have already received hormone therapy will now be eligible for palbociclib on the NHS.
Drug prices in China cut by up to 61 percent for reimbursement scheme list
Top pharmaceutical companies have reduced their drug costs in China by an average of 61 percent, to be added to the reimbursement list in the country.
Political parties focus on R&D and mental health ahead of UK election
The three largest UK political parties have published their manifestos for the upcoming election which focus on various pharma initiatives including the NHS, R&D, drug prices and mental health.
The FDA has approved Exservan™ for the treatment of ALS
The FDA has granted early-action approval to Exservan for the treatment of ALS, which can be administered safely and easily without water.
Generics and biosimilars vital to reduce healthcare costs, finds EC
The EC has released a report that has found generics and biosimilars decrease wasteful spending and maintain health quality in the EU.
FDA issues warning letter for marketing unapproved products
A warning letter has been issued by the FDA for products illegally marketed for the treatment of health conditions, including opioid withdrawal symptoms.
Avacopan Phase III trial meets primary endpoints
A study to demonstrate the safety and efficacy of avacopan has produced topline results, according to the pharmaceutical company developing the drug.
New technique can closely control nanoparticle size and shape
A new technique has been demonstrated that will control the size and shape of nanoparticles which could lead to their use as a form of drug delivery.
Six pharma companies reported to be under investigation for opioid shipments
US prosecutors have handed subpoenas to six pharmaceutical companies and distributors for their role in the opioid crisis, as reported.
Key trends for pharma in 2020 reported from CPhI Worldwide
The content sessions at CPhI Worldwide have revealed the coming trends that the pharmaceutical industry will see next year.
Report predicts the medical marijuana market will reach $3.2bn by 2025
The global medical marijuana market will show impressive growth, a new report has said, but this could be hindered due to some doctors being reluctant to prescribe these products.
